Chen G, Peng J, Xiao Q, et al. - Researchers sought to determine if circulating tumor DNA (ctDNA) has utility in predicting the recurrence risk in patients with stage II/III colorectal cancer (CRC) in this prospective, observational, and multicenter study. In 154 of 240 patients (64.2%), ctDNA was identifiable preoperatively. As shown in all multivariate analyses, ctDNA positivity continued to be the most significant as well as independent predictor of recurrence-free survival following adjustment for recognized clinicopathological risk factors. Experts found that not only high relapse risk was predicted by postoperative serial ctDNA detection but also it revealed disease recurrence ahead of radiological imaging in patients suffering from stage II/III CRC. Overall, ctDNA may be employed to guide the decision-making in postsurgical management.